CR20200576A - Métodos para tratar cáncer - Google Patents

Métodos para tratar cáncer

Info

Publication number
CR20200576A
CR20200576A CR20200576A CR20200576A CR20200576A CR 20200576 A CR20200576 A CR 20200576A CR 20200576 A CR20200576 A CR 20200576A CR 20200576 A CR20200576 A CR 20200576A CR 20200576 A CR20200576 A CR 20200576A
Authority
CR
Costa Rica
Prior art keywords
treating cancer
methods
mpn
formula
therapeutic methods
Prior art date
Application number
CR20200576A
Other languages
English (en)
Inventor
Wayne Rothbaum
Original Assignee
Kartos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kartos Therapeutics Inc filed Critical Kartos Therapeutics Inc
Publication of CR20200576A publication Critical patent/CR20200576A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se describen métodos terapéuticos y composiciones farmacéuticas para tratar cáncer incluido un neoplasma mieloproliferativo (MPN), incluido policitemia vera (PV), trombocitemia esencial (ET), y mielofibrosis primaria en un sujeto humano. En ciertas modalidades, la invención incluye métodos para tratar una MPN utilizando un inhibidor de MDM2 de la Fórmula (I) o Fórmula (II).</p>
CR20200576A 2018-04-30 2019-04-30 Métodos para tratar cáncer CR20200576A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862664673P 2018-04-30 2018-04-30
US201862701088P 2018-07-20 2018-07-20
US201862781942P 2018-12-19 2018-12-19
US201962834848P 2019-04-16 2019-04-16
PCT/US2019/029906 WO2019213074A1 (en) 2018-04-30 2019-04-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CR20200576A true CR20200576A (es) 2021-04-30

Family

ID=68386769

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200576A CR20200576A (es) 2018-04-30 2019-04-30 Métodos para tratar cáncer

Country Status (20)

Country Link
US (1) US20210186946A1 (es)
EP (1) EP3787625A4 (es)
JP (2) JP2021523220A (es)
KR (1) KR20210019422A (es)
CN (1) CN112512525A (es)
AU (1) AU2019263064A1 (es)
BR (1) BR112020022148A2 (es)
CA (1) CA3098606A1 (es)
CL (1) CL2020002833A1 (es)
CO (1) CO2020014599A2 (es)
CR (1) CR20200576A (es)
IL (2) IL278345B2 (es)
JO (1) JOP20200273A1 (es)
MX (1) MX2020011608A (es)
PE (1) PE20211653A1 (es)
PH (1) PH12020551820A1 (es)
SG (1) SG11202010793UA (es)
TN (1) TN2020000210A1 (es)
TW (2) TWI741286B (es)
WO (1) WO2019213074A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547311A (ja) * 2019-09-16 2022-11-11 ノバルティス アーゲー 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
WO2022219128A1 (en) * 2021-04-15 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm
WO2023039160A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating a cancer overexpressing one or more bcl-2 family proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2928477T3 (pl) * 2012-12-07 2020-03-31 Geron Corporation Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
JP6266659B2 (ja) * 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015070224A2 (en) * 2013-11-11 2015-05-14 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CA2931615A1 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
JP6675313B2 (ja) * 2013-12-23 2020-04-01 ノバルティス アーゲー 組合せ医薬
AU2015211021B2 (en) * 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor

Also Published As

Publication number Publication date
TN2020000210A1 (en) 2022-07-01
CO2020014599A2 (es) 2021-02-26
TW201945340A (zh) 2019-12-01
US20210186946A1 (en) 2021-06-24
IL278345A (es) 2020-12-31
EP3787625A1 (en) 2021-03-10
CL2020002833A1 (es) 2021-04-30
JP2024050668A (ja) 2024-04-10
IL308399A (en) 2024-01-01
WO2019213074A1 (en) 2019-11-07
JP2021523220A (ja) 2021-09-02
BR112020022148A2 (pt) 2021-04-13
MX2020011608A (es) 2021-02-17
IL278345B2 (en) 2024-05-01
IL278345B1 (en) 2024-01-01
SG11202010793UA (en) 2020-11-27
EP3787625A4 (en) 2022-01-26
TW202146387A (zh) 2021-12-16
PH12020551820A1 (en) 2021-07-26
CA3098606A1 (en) 2019-11-07
PE20211653A1 (es) 2021-08-24
JOP20200273A1 (ar) 2020-11-01
AU2019263064A1 (en) 2020-12-03
TWI741286B (zh) 2021-10-01
CN112512525A (zh) 2021-03-16
KR20210019422A (ko) 2021-02-22

Similar Documents

Publication Publication Date Title
CR20200576A (es) Métodos para tratar cáncer
MX2022000711A (es) Inhibidores de parp1.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12018501920B1 (en) Bromodomain inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020012503A (es) Métodos de tratamiento de neoplasias mieloproliferativas.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2022001535A (es) Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.
MX2020013621A (es) Composiciones y metodos de tratamiento de vih.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020000402A (es) Nuevos derivados de xantina sustituidos.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA202092550A1 (ru) Способы лечения рака
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.